Roche Holding AG (SWX: ROG)
Switzerland
· Delayed Price · Currency is CHF 266.30
-0.60 (-0.22%)
Jan 21, 2025, 12:07 PM CET
Roche Holding AG Revenue
Roche Holding AG had revenue of 30.76B CHF in the half year ending June 30, 2024, a decrease of -9.27%. This brings the company's revenue in the last twelve months to 60.58B, down -3.12% year-over-year. In the year 2023, Roche Holding AG had annual revenue of 60.44B, down -8.16%.
Revenue (ttm)
60.58B
Revenue Growth
-3.12%
P/S Ratio
3.52
Revenue / Employee
584.73K
Employees
103,605
Market Cap
214.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | 63.75B | 4.25B | 7.15% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novartis AG | 42.18B |
| Lonza Group AG | 6.70B |
| Alcon | 8.25B |
| Galderma Group AG | 3.88B |
| Straumann Holding AG | 2.54B |
| Sonova Holding AG | 3.71B |
| Sandoz Group AG | 9.09B |
| Ypsomed Holding AG | 617.07M |
Roche Holding AG News
- 1 day ago - Roche descendant André Hoffmann on pharma, feuds and family business - Financial Times
- 4 days ago - B-cell Depletion Innovation Research Report 2024: Roche Dominate the Patent Activity in B-cell Depletion Therapy, with a Dip in New Companies Filing Patents in Recent Years - GlobeNewsWire
- 4 days ago - Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug - Benzinga
- 7 days ago - Dyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene Therapy - Business Wire
- 8 days ago - Roche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma - PRNewsWire
- 10 days ago - Danielle Dysinger: Engineering Creativity, Advocacy, and the Great Outdoors - CEOWORLD magazine
- 11 days ago - Roche Finalizes Poseida Acquisition: This Cell Therapy Deal Feels Like A Win/Win - Seeking Alpha
- 12 days ago - Roche's momentum in digital pathology continues with FDA clearance on its high-volume slide scanner - PRNewsWire